← Back to Discover
Flagship Ventures Fund IV General Partner LLC
Period ended Jun 30, 2016 · Latest filing Aug 15, 2016
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Jun 30, 2016: $584,904,000
More quarters will appear as history becomes available.
Top holdings
Top 10 at Jun 30, 2016. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- SERES THERAPEUTICS INC · COM · 81750R102 · shares: $368,438,000
- EDITAS MEDICINE INC · COM · 28106W103 · shares: $120,910,000
- SYROS PHARMACEUTICALS INC · COM · 87184Q107 · shares: $87,241,000
- T2 BIOSYSTEMS INC · COM · 89853L104 · shares: $5,852,000
- ELEVEN BIOTHERAPEUTICS INC · COM · 286221106 · shares: $2,464,000
Filing totals differ
The filing summary reports $584,904,000, while the holdings entries total $584,905,000.
Reported holdings
5 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| SERES THERAPEUTICS INC | COM | 81750R102 | — | 12,682,876 shares | $368,438,000 |
| EDITAS MEDICINE INC | COM | 28106W103 | — | 4,955,316 shares | $120,910,000 |
| SYROS PHARMACEUTICALS INC | COM | 87184Q107 | — | 4,806,656 shares | $87,241,000 |
| T2 BIOSYSTEMS INC | COM | 89853L104 | — | 741,755 shares | $5,852,000 |
| ELEVEN BIOTHERAPEUTICS INC | COM | 286221106 | — | 1,466,417 shares | $2,464,000 |